MedTrace Logo

An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C

NCT01679834 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7500

Last updated 2018-03-01

No results posted yet for this study

Summary

This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C. Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to local guidelines. Data will be collected for 96 weeks.

Conditions

  • Hepatitis C, Chronic

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-24
Primary Completion
2017-07-14
Completion
2017-07-14

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679834 on ClinicalTrials.gov